Incorporating immunological testing, particularly aquaporin-4 (AQP4) antibody status, further improves discrimination between NMOSD, MS, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). This evidence concerns the gene AQP4 and myeloid sarcoma.